Antipsikotiklere Bağlı Hiperprolaktinemi

Öz

Sıklıkla hamilelikte meme bezinin büyümesi, laktasyon için süt sentezi ve hazırlanması gibi görevleri ile bilinen prolaktinin günümüzde, bu etkilerinin dışında da pek çok işleve sahip olduğu bilinmektedir. Psikiyatride sıklıkla kullanılan antipsikotikler ve antidepresanlar da hiperprolaktinemi yapabilmektedir. Özellikle tipik antipsikotiklerin ön hipofizdeki D2 reseptörlerini bloke ederek birincil olarak prolaktin seviyelerini yükselttikleri görüşü mevcuttur. Atipik antipsikotiklerin hiperprolaktinemi üzerine etkileri farklılık gösterir. Hiperprolaktinemi; oligomenore, polimenore ve amenore gibi menstrual düzensizliklere ek olarak galaktore, jinekomasti, cinsel işlev bozuklukları (libidoda azalma, uyarılma ve orgazm bozuklukları), infertilite, kadınlarda akne ve hirşutizm, kilo alımı, obezite ve duygudurum değişikliklerine yol açmaktadır. Uzun süreçte hiperprolaktinemi kemik yoğunluğunda azalma ve osteoporoza yol açabilir. Bu makalede psikiyatri hekimlerince sıklıkla kullanılan antipsikotiklerin hiperprolaktinemi yan etkileri ve bu yan etkiler üzerine yapılan araştırmalar gözden geçirilecek, hiperprolaktinemi sonucu gelişen belirtilere yönelik yaklaşımlara değinilecektir.

Anahtar Kelimeler

• Antipsikotik ilaçlar, prolaktin, hiperprolaktinemi

Antipsychotic-induced Hyperprolactinemia

Öz

Prolactin provides the growth of the mammary gland during pregnancy and synthesis and preparation of breast milk for lactation. Antipsychotics and antidepressants that are frequently used in psychiatry, cause hyperprolactinemia. The prevalent opinion is that especially typical antipsychotics increase prolactin levels primarily by blocking D2 receptors in the anterior pituitary. The effects of atypical antipsychotics on hyperprolactinemia vary. Hyperprolactinemia causes galactorrhea, gynecomastia, sexual dysfunction, infertility, acne, hirsutism in women, weight gain, obesity and mood changes in addition to menstrual irregularities such as oligomenorrhea, polymenorrhea and amenorrhea. In the long term, hyperprolactinemia may cause reduction in bone density and osteoporosis. Hyperprolactinemia as a side effect of antipsychotics drugs and its treatment will be reviewed in this article.

Anahtar Kelimeler

• Antipsychotic drugs, prolactin, hyperprolactinemia

Kaynakça

1. Abraham G, Friedman RH, Verghese C, De Leon J (1995) Osteoporosis and schizophrenia: can we limit known risk factors? Biol Psychiatry, 38:131-132.
2. Adler RA, Evani R, Mansouri A, Krieg RJ (1998) Relative effects of prolactin excess and estrogen deficiency on bone in rats. Metabolism, 47:425-428.
3. Altındağ Ö, Altındağ A, Vırıt O, Savaş HA, Yılmaz M, Bozgeyik Ö et al. (2009) Antipsikotik ilaç kullanan şizofreni hastalarında kemik mineral yoğunluğu. Klinik Psikofarmakoloji Bülteni, 19:402-406.
4. Ayhan MG, Uğuz F, Kaya N (2011) Risperidona bağlı gelişen hiperprolaktineminin tedaviye aripiprazol eklenmesi ile düzelmesi. Genel Tıp Dergisi, 21:65-69.
5. Bargiota SI, Bonotis KS, Messinis IE, Angelopoulos NV (2013) The effects of antipsychotics on prolactin levels and women’s menstruation. Schizophrenia Research and Treatment, 2013:502697.
6. Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C (2014) Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance. Encephale, 40:86-94.
7. Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM et al. (1999) Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry, 156:294-298.
8. Bulut SD, Tüzer V, Ak M, Ak E, Kısa C, Aydemir Ç et al (2014) Şizofreni tanılı hastalarda prolaktini yükselten ve az etkileyen antipsikotiklerin prolaktin seviyesi ve kemik mineral yoğunluğu üzerine etkileri. Nöropsikiyatri Arşivi, 51:205-210.

9. Crawford AM, Beasley CM, Jr. Tollefson GD (1997) The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res, 26:41-54.
10. Compton MT, Miller AH (2002) Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull, 36:143- 164.
11. Coss D, Yang L, Kuo CB, Xu X, Luben RA, Walker AM (2000) Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol Endocrinol Metab, 279:1216-1225.
12. Checkley S (1991) Neuroendocrine effects of psychotropic drugs. Baillieres Best Pract Res Clin Endocrinol Metab, 5:15-33.
13. David SR, Taylor CC, Kinon BJ, Breier A (2000) The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther, 22:1085-1096.
14. Feldman D, Goldberg JF (2002) A preliminary study of the relationship between clozapine-induced weight gain and menstrual irregularities in schizophrenic, schizoaffective, and bipolar women. Ann Clin Psychiatry, 14:17–21.
15. Fell MJ, Neill JC, Marshall KM (2004) Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats. Eur Neuropsychopharmacol, 14:385–392.
16. Freeman ME, Banks JA (1980) Hypothalamic sites which control the surges of prolactin secretion induced by cervical stimulation. Endocrinology, 106:668-673.
17. Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev, 80:1523-1631.
18. Glazer WM, Naftolin F, Morgenstern H, Barnea ER, MacLusky NJ, Brenner LM (1985) Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology, 10:345-350.
19. Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K et al. (1998) An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol, 18:296–304.
20. Green AI, Brown WA (1988) Prolactin and neuroleptic drugs. Endocrinol Metab Clin North Am, 17:213-223.
21. Grunder G, Wetzel H, Schlosser R, Anghelescu I, Hillert A, Lange K et al. (1999) Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry, 45:89-97.
22. Haddad PM, Hellewell JS, Wieck A (2001) Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports. J Psychopharmacol, 15:293-295.
23. Haddad PM, Wieck A (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs, 64:2291-2314.
24. Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y et al. (1995) Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 57:485-491.
25. Halbreich U, Shen J, Panaro V (1996) Are chronic psychiatric patients at increased risk for developing breast cancer?. Am J Psychiatry, 153:559-560.
26. Halbreich U, Palter S (1996) Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull, 22:447-454.
27. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE (1995) Reproductibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev, 4:649-654.
28. Harlan RE, Shivers BD, Fox SR, Kaplove KA, Schachter BS, Pfaff DW (1989) Distribution and partial characterization of immunoreactive prolactin in the rat brain. Neuroendocrinology, 49:7-22.
29. Hui SL, Slemenda CW, Johnston CC (1988) age and bone mass as predictors of fracture in a prospective study. J Clin Invest, 81:1804-1809.
30. Ishizuka B, Quigley ME, Yen SS (1983) Pituitary hormone release in response to food ingestion: evidence for neuroendocrine signals from gut to brain. J Clin Endocrinol Metab, 57:1111-1116.
31. Jeffcoate SL, Bacon RRA, Beastall GH, Diver MJ, Franks S, Seth J (1986) Assays for prolactin: guidelines for the provision of a clinical biochemistryservice. Ann Clin Biochem, 23:638-651.
32. Kaneda Y, Fujii A (2000) Effects of chronic neuroleptic administration on the hypothalamo-pituitary-gonadal axis of male schizophrenics. Prog Neuropsychopharmacol Biol Psychiatry, 24:251-258.
33. Kaneda Y, Fujii A (2002) Gynecomastia with sulpiride. J Clin Pharm Ther, 27:75-77.
34. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry, 158:360-369.
35. Karakuş G, Tamam L, Zengin M (2009) Şizofreni hastalarında antipsikotik kullanımına bağlı hiperprolaktinemi ve kemik metabolizma bozuklukları. Anadolu Psikiyatri Dergisi, 10 : 336-342.
36. Kinon BJ, Gilmore JA, Liu H, Halbreich UM (2003) Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology, 28:55-68.
37. Kleinberg DL, Davis JM, De Coster R, Van Baelen B, Brecher M (1999) Prolactin levels and adverse events in patients treated with risperidone. J Psychopharmacol, 19:57-61.
38. Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW (1980) Decreased bone density in hyperprolactinemic women. N Engl J Med, 303:1511-1514.
39. Knegtering H, Van Der Moolen AE, Castelein S, Kluiter H, Van Den Bosch RJ (2003) What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology, 28:109-123.
40. Knegtering H, van den Bosch R, Castelein S, Bruggeman R, Sytema S, van Os J (2008) Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin?. Psychoneuroendocrinology, 33:711-717.
41. Kondo T, Otani K, Ishida M, Tanaka O, Kaneko S, Fukushima Y (1994) Adverse effects of zotepine and their relationship to serum concentrations of the drug and prolactin. Ther Drug Monit, 16:120-124.
42. Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy AS (1992) A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol, 19:603-606.
43. La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grözinger M (2013) Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics, Pharmacopsychiatry, 46:201–208.
44. Lee BH, Kim YK (2006) The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharmacol Biol Psychiatry, 30:658–662.
45. Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res, 35:51-68.
46. Lindamer LA, Bailey A, Hawthorne W, Folsom DP, Gilmer TP, Garcia P et al. (2003) Gender differences in characteristics and service use of public mental health patients with schizophrenia. Psychiatr Serv, 54:1407-1409.
47. MacLeod RM, Login I (1976) Control of prolactin secretion by the hypothalamic catecholamines. Adv Sex Horm Res, 2:211-231.
48. Mai LM, Shieh KR, Pan JT (1994) Circadian changes of serum prolactin levels and tuberoinfundibular dopaminergic neuron activities in ovariectomized rats treated with or without estrogen: the role of the suprachiasmatic nuclei. Neuroendocrinology, 60:520-526.
49. Matsuoka I, Nakai T, Miyake M, Hirai M, Ikawa G (1986) Effects of Bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence. Psychiatry Clin Neurosci, 40:639-646.
50. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V (2004) Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry, 184:503-508.
51. Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS (1979) Effect of clozapine on human serum prolactin levels. Am J Psychiatry, 136:1550-1555.
52. Coyle JT, Enna SJ (1983) Neuroleptics: Neurochemical, Behavioural and Clinical Perspectives. New York, Raven Press.
53. Molitch ME (2005) Medication-induced hyperprolactinemia. Mayo Clin Proc, 80:1050-1057.
54. Montejo Á L, Majadas S, Rico-Villademoros F, Lorca G, De La Gándara J, Franco M et al. (2010) Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sex Med, 7:3404-3413.
55. Naidoo U, Goff DC, Klibanski A (2003) Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology, 28(Suppl 2):97-108.
56. Nathan RS, Asnis GM, Dyrenfurth I, Halpern FS, Halbreich U, Ostrow LC (1980) Plasma prolactin and testosterone during penfluridol treatment. Lancet, 2:94.
57. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al. (2001) Effect of parathyroid hormone on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
58. Nonacs RM (2000) Antipsychotic treatment and menstrual irregularity. 153rd Annual Meeting of the American Psychiatric Association, 13-18 May 2000, USA.
59. Okyay E, Gülekli B (2012) Kadında hiperprolaktinemi ve medikal tedavi.Türkiye Klinikleri Jinekoloji Obstetrik Özel Dergisi, 5(3):66- 80.
60. Pahuja DN, DeLuca HF (1981) Stimulation of intestinal calcium transport and bone calcium mobilization by prolactin in vitamin D- deficient rats. Science, 214:1038-1039.
61. Pellegrini I, Lebrun JJ, Ali S, Kelly PA (1992) Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinol, 6:1023-1031.
62. Perovich RM, Lieberman JA, Fleischhacker WW, Alvir J (1989) The behavioral toxicity of bromocriptine in patients with psychiatric illness. J Clin Psychopharmacol, 9:417-422.
63. Petty RG (1999) Prolactin and antipsychotic medications: mechanism of action. Schizophr Res, 35:67-73.
64. Pollock A, McLaren EH (1998) Serum prolactin concentration in patients taking neuroleptic drugs. Clin Endocrinol, 49:513-516.
65. Rajnish R, Singh SB (2008) Hyperprolactinaemia with amisulpride. Indian J Psychiatry, 50:54–56.
66. Richards JS, Williams JJ (1976) Luteal cell receptor content for prolactin (PRL) and luteinizing hormone (LH): regulation by LH and PRL. Endocrinology, 99:1571-1581.
67. Saitis M, Papazisis G, Katsigiannopoulos K, Kouvelas D (2008) Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia. Psychiatry Clin Neurosci, 62:624.
68. Seeman MV (1996) The role of estrogen in schizophrenia. J Psychiatry Neurosci, 21:123.
69. Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R et al. (2001) A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol, 11:415-424.
70. Shennan DB (1994) Regulation of water and solute transport across mammalian plasma cell membranes by prolactin. J Dairy Res, 61:155-166.
71. Skopek M, Manoj P (2010) Hyperprolactinaemia during treatment with paliperidone. Australas Psychiatry, 18:261–263.
72. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG (1997) Quetiapine in patients with schizophrenia. A high-and low-dose double-blind comparison with placebo. Arch Gen Psychiatry, 54:549-557.
73. Smith SM, O'Keane V, Murray R (2002) Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry, 181:49-55.
74. Struman I, Bentzien F, Lee H, Mainfroid V, D’Angelo G, Goffin V (1999) Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci, 96:1246-1251.
75. Sun FG, Dong RL, Zhao Z, Pan M (2009) Efficacy and adverse reactions of ziprasidone in 30 female patients with schizophrenia. Chinese Journal of New Drugs and Clinical Remedies, 5:103-107.
76. Terkel J, Blake CA, Sawyer CH (1972) Serum prolactin levels in lactating rats after suckling or exposure to ether. Endocrinology, 91:49-53.
77. Tollefson GD, Kuntz AJ (1999) Review of recent clinical studies with olanzapine. Br J Psychiatry, 37:30-35.
78. Tollin SR (2000) Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest, 23:765-770.
79. Vekemans M, Delvoye P, L'Hermite M, Robyn C (1977) Serum prolactin levels during the menstrual cycle. J Clin Endocrinol Metab, 44:989-993.
80. Veldhuis JD, Evans WS, Stumpf PG (1989) Mechanisms that subserve estradiol's induction of increased prolactin concentrations: evidence of amplitude modulation of spontaneous prolactin secretory bursts. Am J Obstet Gynecol, 161:1149-1158.
81. Waldstreicher J, Duffy JF, Brown EN, Rogacz S, Allan JS, Czeisler CA (1996) Gender differences in the temporal organization of prolactin (PRL) secretion: evidence for a sleep-independent circadian rhythm of circulating PRL levels- a clinical research center study. J Clin Endocrinol Metab, 81:1483-1487.
82. Windgassen KW, Wesselmann U, Mönking H (1996) Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiology, 33:142-146.
83. Winters SJ, Troen P(1984) Altered pulsatile secretion of luteinizing hormone in hypogonadal men with hyperprolactinaemia. Clin Endocrinol, 21:257-63.
84. Wistedt B, Wiles D, Kolakowska T (1981) Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet, 1(8230):1163.
85. Yen S, Jaffe R (1991) Reproductive Endocrinology, 3rd ed. Philadelphia, WB Saunders.
86. Zelaschi NM, Delucchi GA, Rodriguez JL (1996) High plasma prolactin levels after long-term neuroleptic treatment. Biol Psychiatry, 39:900-901.